TPBG
NVCR icon

Turning Point Benefit Group’s NovoCure NVCR Stock Holding History

Turning Point Benefit Group’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3
Closed -$38 – 560
2025
Q4 		$38 Hold
3
– – ﹤0.01% 834
2025
Q3 		$41 Buy
+3
New +$40 ﹤0.01% 748

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Turning Point Benefit Group's NVCR Position: Q1 2026 in Review

Turning Point Benefit Group sold out of NovoCure (NVCR) in Q1 2026, closing a stake of 3 shares — an estimated $38 sold.

Turning Point Benefit Group first reported a position in NVCR in Q3 2025 and held it in 2 quarters. The position peaked at $41 in Q3 2025. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • Turning Point Benefit Group reported no remaining NovoCure position as of Q1 2026 after selling out during the quarter.
  • Turning Point Benefit Group sold 3 NovoCure shares in Q1 2026, an estimated $38.
  • Turning Point Benefit Group first reported a position in NovoCure in Q3 2025 and held it in 2 quarters.
  • Turning Point Benefit Group's NovoCure position peaked at $41 in Q3 2025.
  • 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Turning Point Benefit Group's 13F filing for Q1 2026, filed 12 May 2026.